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httcense.Abstract Aim of work: The aim of this study is to investigate the efﬁcacy of nebulized magnesium
sulphate as a bronchodilator in acute asthma as compared to nebulized salbutamol.
Subjects and methods: This was a randomized controlled study conducted in El-Giza Chest Hos-
pital Emergency Department between January 2010 and June 2011. Randomization was achieved
by closed envelope technique. This study involved 48 known bronchial asthma patients presenting
with acute or subacute exacerbations. Patients were divided into Control group (A) and Study
group (B). Initial assessment of all patients included history, clinical examination (auscultation,
respiratory rate (RR), heart rate (HR) and working of accessory muscles). In addition to measure-
ment of peak expiratory ﬂow rate (PEFR) and oxygen saturation (SO2). Patients received standard
treatment for their acute attacks in the form of Sodium hydrocortisone hemisuccinate 100 mg every
6 hours, Supplemental oxygen and nebulized bronchodilator which was salbutamol in group (A) in
the form of 4 doses of nebulized solution 0.5 gm% (each dose 1 ml containing 5 mg salbutamol)
twenty minutes apart and Magnesium sulphate in group (B) in the form of 4 doses of nebulized
solution 10 gm% (each dose 1 ml containing 100 mg magnesium sulphate) twenty minutes apart.
Reassessment of the patients was performed after 2 hours to detect improvement.
Results: The percent change in PEFR in Group A was signiﬁcantly higher than that in Group B
(58.90% and 13.92% respectively, p value 0.00). There was a statistically signiﬁcant reduction in the
ﬁnal mean HR in Group B compared to Group A (85 bpm and 96.1 bpm respectively, p value01116000300.
(M.M. Kamel).
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30 E.A. Abdelnabi et al.0.011). There was a signiﬁcant reduction in mean ﬁnal RR in Group A compared to Group B
(22.17 bpm. and 25 bpm respectively, p value 0.002).There was a signiﬁcant increase in oxygen sat-
uration (SO2) in both groups.
Conclusion: The use of MgSO4 by nebulization in patients with acute asthma attacks results in
improvement of clinical condition, increase in peak expiratory ﬂow rate (PEFR), reduction in heart
rate (HR), reduction in respiratory rate (RR) and improvement in oxygen saturation (SO2). The
increase in PEFR (bronchodilatory effect) was signiﬁcantly less than that achieved in patients receiving
the usual treatment with Short acting b2 agonists, e.g. salbutamol, when either agents were used alone.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Asthma exacerbations are acute or subacute episodes of
breathlessness, cough, wheezing, and chest tightness, or any
combination of these symptoms. Exacerbations are associated
with airways obstruction that should be documented and
quantiﬁed by PEF or FEV1 measurement [1].
Objective measures of airways obstruction in most asthmat-
ics are considered more reliable to indicate the severity of an
exacerbation than changes in the severity of symptoms. The
intensity of asthma exacerbations may vary from mild to se-
vere. Among patients attending an emergency department,
the severity of obstruction in terms of FEV1 is, on average,
30–35% of predicted normal [1].
In asthmatic subjects who die suddenly of an asthma attack,
the peripheral airways frequently exhibit occlusion of the bron-
chial lumen by inspissated secretions, thickened smooth muscles,
and bronchial wall inﬂammatory inﬁltration and edema [2].
These changes observed in the asthmatic airways support
the hypothesis that peripheral airways occlusion forms the
pathologic basis of the gas exchange abnormalities observed
in acute, severe asthma [2].
Hypoxemia is therefore common in every asthmatic crisis of
some severity; mild hypoxia is easily corrected with the admin-
istration of relatively low concentrations of supplemental oxy-
gen. More severe hypoxemia and the need for higher
concentrations of supplemental oxygen may relate to some
contribution of shunt physiology [3].
Although arterial blood gas analysis is useful in the man-
agement of patients with acute, severe asthma, it is not predic-
tive of outcome. Arterial blood gas determinations are
necessary in the more severe asthmatic crisis, when oxygen sat-
uration is lower than 90%, and in the case of no response or
deterioration. In such cases, analysis of blood gases usually re-
veals severe hypoxemia with arterial oxygen (PaO2) lower than
60 mmHg, hypocapnia and respiratory alkalosis with or with-
out compensatory metabolic acidosis. As the severity of air-
ﬂow obstruction increases, PaCO2 ﬁrst normalizes and
subsequently increases. The transition from hypocapnia to
normocapnia is an important sign of severe clinical deteriora-
tion and the appearance of hypercapnia probably indicates the
need for mechanical ventilation [4].
Clinically, patients with acute, severe asthma appear seri-
ously dyspneic at rest, are unable to talk with sentences or
phrases, are agitated and sit upright [5].
Drowsiness or confusion are always ominous signs and de-
note imminent respiratory arrest. Vital signs in acute severe
asthma are: respiratory rate usually >30 breaths/min; heartrate >120 beats/min; wheezing throughout both the inspira-
tion and the expiration; use of accessory respiratory muscles;
evidence of suprasternal retractions; and pulsus paradoxus
>12 mmHg. Pulsus paradoxus can be a valuable sign of asth-
ma severity but its detection should not delay prompt treat-
ment [5].
Paradoxical thoracoabdominal movement and the absence
of pulsus paradoxus suggest ventilatory muscle fatigue and, to-
gether with the disappearance of wheeze and the transition
from tachycardia to bradicardia, represent signs of imminent
respiratory arrest. The usual cardiac rhythm in acute, severe
asthma is sinus tachycardia, although supraventricular
arrhythmias are not uncommon. Less frequently ventricular
arrhythmias may be observed in elderly patients [5].
Early treatment of asthma exacerbations should be the best
strategy for management [6].
In the emergency department, a brief history regarding time
of onset, cause of exacerbation, severity of symptoms (especially
in comparison to previous attacks), prior hospitalizations and/or
emergency department visits for asthma, prior intubation or
intensive care admission, and complicating illness may be useful
for treatment decisions. The primary therapies for acute severe
asthma include, the administration of oxygen, inhaled b2-ago-
nists, and systemic corticosteroids. The intensity of pharmaco-
logical treatment and patient’s surveillance should correspond
to the severity of the exacerbation [7].
Combining nebulized ipratropium bromide with a nebu-
lized b2 agonist produces signiﬁcantly greater bronchodilation
than a b2 agonist alone, leading to a faster recovery and short-
er duration of admission [8].
Oxygen treatment (by nasal cannulae or mask) is recom-
mended for most patients who present with severe exacerba-
tion in order to maintain oxygen saturation >90% (>95%
in pregnant women and in patients with coexistent cardiac dis-
ease) [7].
MgSO4 is an agent that has been proposed as a possible
additive treatment in patients with acute asthma and has been
shown to be effective in patients with severe acute asthma
when delivered parenterally [9].
Magnesium is involved with cellular homeostasis through its
role as an enzymatic cofactor, as well as being involved in acetyl-
choline and histamine release, from cholinergic nerve terminals
and mast cells, respectively. Investigators have proposed that
the effect of MgSO4 is related to its ability to block the calcium
ion inﬂux to the smooth muscles of the respiratory system. Mag-
nesium may increase the bronchodilator response to salbutamol
in acute asthma by increasing the afﬁnity of b receptors to salbu-
tamol or by upregulating b receptors [10].
Nebulized magnesium sulphate versus nebulized salbutamol in acute bronchial asthma 31Nebulized magnesium sulphate has bronchodilator effects
similar to those of nebulized salbutamol. Nebulized MgSO4
appears to be effective and safe to administer to patients expe-
riencing asthma exacerbations [11].
Intravenous magnesium is contraindicated in patient with
renal failure, and systemic toxicity due to high dose of magne-
sium limits the application in certain circumstances. Nebulized
magnesium sulphate may be a solution in such a condition, as
high concentration of magnesium may be delivered locally
without causing systemic side effect [12].
Aim of the work
The aim of this study is to investigate the efﬁcacy of nebulized
magnesium sulphate as a bronchodilator in acute asthma as
compared to nebulized salbutamol.
Subjects and Methods
This was a randomized controlled study conducted in El-Giza
Chest Hospital Emergency Department between January 2010
and June 2011. Randomization was achieved by closed enve-
lope technique. This study involved 48 known bronchial asth-
ma patients presenting with acute attacks.
Inclusion criteria
Adult cases with acute or subacute exacerbations according to
Global Initiative for Asthma (GINA) Guidelines 2010.Table 1 Statistical comparison between group A and group B
regarding age.
Group A Group B Man-Whitney U p Value
Age mean 30.08 33.08 238 0.301
N 24 24
Std. Deviation 12.003 8.345
N= number of cases.Exclusion criteria
1. Fever
2. Smokers
3. COPD patients
4. Pneumonia
5. Cardiac, Renal or Hepatic insufﬁciency
6. Pregnant or Lactating mothers
7. Respiratory failure
Patients were divided into Control group (A) and Study
group (B). Initial assessment of all patients included history,
clinical examination (auscultation, respiratory rate, heart rate
and working of accessory muscles). In addition to measure-
ment of peak expiratory ﬂow rate and oxygen saturation.
Patients received standard treatment for their acute attacks
in the form of:
1. Sodium hydrocortisone hemisuccinate 100 mg every
68 hours.
2. Supplemental oxygen to achieve oxygen saturation more
than 90%.
3. Nebulized bronchodilator which was salbutamol in group
(A) in the form of 4 doses of nebulized solution 0.5 gm%
(each dose 1 ml containing 5 mg salbutamol) twenty min-
utes apart and magnesium sulphate in group (B) in the form
of 4 doses of nebulized solution 10 gm% (each dose 1 ml
containing 100 mg magnesium sulphate) twenty minutes
apart.Reassessment of the patients was performed after 2 hours
to detect improvement.
Patients whose PEFR did not show any improvement and
showed clinical deterioration at the end of the 1 hours were gi-
ven supplemental treatment immediately which consisted of
salbutamol nebulization and aminophylline infusion (5 mg/kg
loading dose over 20 min unless on maintenance oral therapy,
then infusion of 0.5–0.7 mg/kg/hr). Arterial blood gases
(ABG) was withdrawn to assess need for admission to inten-
sive care unit (ICU).
PEFR was monitored with hand held mini-wright peak
ﬂow meter with using values mentioned by Gore et al. [13]
as a reference range.
Results
Group A ¼ salbutamol groupð24patientsÞ
Group B ¼ magnesium sulphate groupð24patientsÞDiscussion
Intravenous magnesium sulfate is commonly used as a treat-
ment for an acute asthma attack, but doctors don’t typically
use the chemical compound as an inhaled medication because
potential health beneﬁts have not yet been deﬁnitely proven
[14].
Most acute asthma attacks improve when treated with an
inhaled short-acting beta-agonist, such as albuterol, a com-
monly used asthma medication that relaxes airway muscles
and dilates or enlarges breathing passages. Severe asthma at-
tacks often require additional forms of treatment, which may
include corticosteroids, magnesium sulfate and mechanical
ventilation, depending on the severity of the symptoms [14].
The results of our study show that the use of MgSO4 by
nebulization results in improvement of clinical condition, in-
crease in peak expiratory ﬂow rate (PEFR), reduction in heart
rate (HR), reduction in respiratory rate (RR) and improve-
ment in oxygen saturation (SO2). The increase in PEFR was
signiﬁcantly less than that achieved in patients receiving the
usual treatment with short acting b2 agonists (see Table 1).
Looking at Tables 2 and 3 the PEFR in group (A) before
treatment was signiﬁcantly less than that in group (B). This de-
noted that patients had a more degree of airway obstruction in
the salbutamol group. After treatment there was no signiﬁcant
difference, once again indicating that the increase in PEFR in
salbutamol group was high.
Tables 4 and 5 showed that there was a statistically signif-
icant improvement in PEFR% in both groups. Thus, the use of
either inhaled salbutamol or MgSO4 improved airway
obstruction.
Table 2 Statistical Comparison between group A and group B
regarding basal peak expiratory ﬂow rate (PEFR) percentages.
Group A Group B Man-Whitney U p Value
Age mean 48.46 61.13 169.5 0.014a
N 24 24
Std. Deviation 12.914 16.369
a Statistically signiﬁcant = p value < 0.05.
Table 3 Statistical comparison between group A and group B
regarding ﬁnal PEFR percentages.
Group A Group B Man-Whitney U p Value
Age mean 86.96 68.25 225 0.194
N 24 24
Std. Deviation 65.972 17.048
Table 4 Statistical Comparison between basal and ﬁnal
PEFR percentages in group A.
Basal Final p Value
PEFR% mean 48.46 86.96 < 0.001a
N 24 24
Std. Deviation 12.914 65.972
a Statistically signiﬁcant = p value < 0.05.
Table 5 Statistical Comparison between basal and ﬁnal
PEFR percentages in group B.
Basal Final p Value
PEFR% mean 61.13 68.25 < 0.001a
N 24 24
Std.Deviation 16.369 17.048
a Statistically signiﬁcant = p value < 0.05.
Table 6 Statistical comparison between group A and group B
regarding percent change in PEFR.
Group A Group B Man-Whitney U p Value
PEFR%change mean 58.90 13.917 53.5 < 0.001a
N 24 24
Std.Deviation 44.2914 15.7445
a Statistically signiﬁcant = p value < 0.05.
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in group (A) was signiﬁcantly higher than that in group (B).
This denoted that salbutamol was more effective as a broncho-
dilator than MgSO4 with a much higher effect on airway
obstruction.
The results obtained in Tables 4–6 agreed with a single
blind study conducted by Tanmaya et al.[15]. They evaluated
the efﬁcacy of nebulized magnesium sulphate in the treatment
of severe asthma in comparison to nebulized salbutamol. 49
patients participated in this study and were divided into two
groups, 25 patients received 4 nebulizations of salbutamol
and 24 patients received MgSO4 nebulizations. Patients were
monitored with respect to PEFR, HR, RR, blood pressure,
presence of cyanosis, SO2, clinical examination of respiratory
system and ﬁschl index (at 0 and 120 min) .The ﬁschl index in-
cludes 7 clinical and symptomatic ﬁndings such as: dyspnea,
accessory muscle use, wheeze, heart rate P120/min, respira-
tory rate P30, pulsus paradoxicus P18 mmHg and PEFR
6120 l/min. The presence of each ﬁnding scores 1 point and
a total score of 4 or more imply severe asthma. Patients in both
groups showed signiﬁcant improvement in all the above men-tioned parameters. However, comparison between the 2
groups revealed that salbutamol was better than MgSO4 in
the management of acute exacerbations of bronchial asthma.
The results of our study as shown in Tables 4 and 5 also
agreed with a study conducted by Mangat et al. [16] whom
investigated the efﬁcacy of nebulized MgSO4 as a bronchodila-
tor in acute asthma as compared to nebulized salbutamol.
Their study was a randomized, double-blind, controlled clini-
cal trial. They enrolled 33 asthmatic patients aged 12-60 years
in acute exacerbation. Patients were randomized to receive
treatment with serial nebulization of either 3 ml (3.2% solu-
tion, 95 mg) MgSO4 solution or 3 ml (2.5 mg) salbutmol solu-
tion. They noted a signiﬁcant improvement in PEFR and
decrease in RR in each group separately but there was no sig-
niﬁcant difference between both groups which disagree with
our study as shown in Table 6. This may be explained by the
fact that as they used half the dose of salbutamol that we used
in our study; similar doses of salbutamol could have caused a
much more signiﬁcant bronchodilator effect.
Our results in Table 6 disagreed with Dadhich et al. [17]
whom conducted a study to assess the efﬁcacy of nebulized
magnesium sulphate in acute severe asthma. They randomly
allocated 71 patients into 3 groups. Group A was nebulized
with salbutamol, Group B with salbutamol & MgSo4 and
Group C by MgSo4 alone. Parameters measured included
PEFR, FEV1, FVC FEV1/FVC at baseline, 10 & 20 min inter-
val along with vital parameters and side effects.
They observed an insigniﬁcant increase in all parameters
(PEFR, FEV1, FVC, FEV1/FVC) in all three groups. How-
ever, the mean% increase over baseline was quite signiﬁcant
at 10 & 20 min interval in Group B & Group C where MgSo4
was used. MgSo4 induced greater bronchodilation in those pa-
tients having baseline PEFR< 50% in contrast to salbutamol.
No signiﬁcant changes in vital parameters were noticed.
They concluded that MgSo4 induced greater bronchodila-
tion in patients with acute severe asthma. No additional side
effects were noticed either alone or with salbutamol. Results
were good & early but unsustainable. So MgSo4 may be used
as an adjunct for standard treatment in management of acute
severe asthma.
In the two studies by Blitz et al. [10] and Rowe et al. [11],
the efﬁcacy of nebulized salbutamol was found to be equal
to that of nebulized magnesium sulphate with no treatment
beneﬁt of either agent used alone. Thus, treatment with nebu-
lized MgSo4 should be considered as an addition to that with
inhaled B2 agonists in patients experiencing asthma exacerba-
tions [10].
The combination of nebulized MgSo4 and salbutamol was
also dealt with in a study by Hughes et al. [18]. 52 patients with
severe exacerbations of asthma presenting to the emergency
departments were enrolled in a randomised double-blind pla-
cebo-controlled trial. The patients received 2Æ5 mg nebulized
Table 9 Statistical comparison between basal and ﬁnal HR in
group B.
Basal Final p Value
HR mean 89.17 85 0.005*
N 24 24
Std. Deviation 10.865 11.018
* Statistically signiﬁcant = p value < 0.05.
Table 10 Statistical comparison between group A and group
B regarding ﬁnal HR.
Group A Group B Man-Whitney U p Value
HR ﬁnal mean 96.13 85.00 165 0.011a
N 24 24
Std. Deviation 14.220 11.018
a Statistically signiﬁcant = p value < 0.05.
Table 11 Statistical comparison between group A and group
B regarding basal RR.
Group A Group B Man-Whitney U p Value
RR basal mean 28.08 26.25 230.5 0.234
N 24 24
Std. Deviation 5.500 6.095
Table 12 Statistical comparison between group A and group
B regarding ﬁnal RR.
Group A Group B Man-Whitney U p Value
RR ﬁnal mean 22.17 25.00 135 0.002a
N 24 24
Std.Deviation 12.433 5.357
a Statistically signiﬁcant = p value < 0.05.
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phate or isotonic saline on three occasions at 30 min intervals.
The primary outcome measure was FEV1 at 90 min. They con-
cluded that use of isotonic magnesium as an adjuvant to neb-
ulized salbutamol results in an enhanced bronchodilator
response in treatment of severe asthma.
Nannini et al. [19] enrolled 35 patients suffering from asth-
ma. The patients were randomized to receive a one-time dose
of 2.5 mg of albuterol. The albuterol dose was diluted in
3 ml of 0.9% sodium chloride or 3 ml of isotonic magnesium
sulfate. The magnesium group demonstrated signiﬁcant
improvements in PEFR compared with the control group.
They concluded that when nebulized magnesium and albuterol
were used together, a higher peak ﬂow could be achieved in
comparison to albuterol plus 0.9% sodium chloride.
In our study Table 7, the mean basal heart rate (HR) in sal-
butamol group was signiﬁcantly higher than that in MgSo4
group. This denoted that in general the asthmatic attack was
more severe in patients of the salbutamol group. This also ex-
plains why the mean basal PEFR in that group was much low-
er than Group B.
In Tables 8–10, the HR decreased in both groups. The reduc-
tion was statistically signiﬁcant in Group B but not in Group A.
This could be explained by stimulation of ß2-receptors of the
heart, as a side effect, in patients receiving salbutamol (Group
A). This agreed with Mangat et al. [16] whom also found a sig-
niﬁcant reduction in HR in patients treated with inhaled MgSo4
only. This ﬁnding illustrates the fact that nebulized MgSo4 can
be used safely in cardiac patients (see Table 11).
In Table 12 we noted a signiﬁcant reduction in mean ﬁnal
respiratory rate (RR) in Group A compared to Group B, cor-
relating with better clinical improvement in that group (see Ta-
bles 13–15).
In Tables 16–18 there was a signiﬁcant increase in oxygen
saturation (SO2) in both groups. This conﬁrms the efﬁcacy
of both drugs as effective bronchodilators.
Looking to Table 19 there were 4 patients in group A whom
presented with a severe attack (PEFR<50%). They were dis-
tressed with working accessory respiratory muscles. They
needed supplementel therapy in the form of frequent salbuta-
mol nebulization and aminophylline infusion (5 mg/kg loading
dose over 20 min, then infusion of 0.5–0.7 mg/kg/hr). This ex-Table 7 Statistical comparison between group A and group B
regarding basal HR.
Group A Group B Man-Whitney U p Value
HRbasal mean 97.08 89.17 188 0.039a
N 24 24
Std.Deviation 14.569 10.865
a Statistically signiﬁcant = p value < 0.05.
Table 8 Statistical Comparison between basal and ﬁnal HR in
group A.
Basal Final p Value
HR mean 97.08 96.13 0.071
N 24 24
Std. Deviation 14.569 14.220
Table 13 Statistical comparison between basal and ﬁnal RR
in group A.
Basal Final p Value
RR mean 28.08 22.17 < 0.001a
N 24 24
Std. Deviation 5.500 12.433
a Statistically signiﬁcant = p value < 0.05.
Table 14 Statistical comparison between basal and ﬁnal RR
in group B.
Basal Final p Value
RR mean 26.25 25.00 0.106
N 24 24
Std. Deviation 6.095 5.357
Table 15 Statistical comparison between group A and group
B regarding basal SO2.
Group A Group B Man-Whitney U p Value
SO2 basal mean 93.33 94.38 162.5 0.0113
N 24 24
Std.Deviation 1.377 8.365
Table 16 Statistical comparison between group A and group
B regarding ﬁnal SO2.
Group A Group B Man-Whitney U p Value
SO2 ﬁnal mean 96 96.46 218 0.132
N 24 24
Std.Deviation 0.933 1.414
Table 17 Statistical comparison between basal and ﬁnal SO2
in group A.
Basal Final p Value
SO2 mean 94.38 96 < 0.001
a
N 24 24
Std.Deviation 1.377 0.933
a Statistically signiﬁcant = p value < 0.05.
Table 18 Statistical Comparison between basal and ﬁnal SO2
in group B.
Basal Final p Value
SO2 mean 93.33 96.46 0.014
a
N 24 24
Std. Deviation 8.365 1.414
a Statistically signiﬁcant = p value < 0.05.
Table 19 Statistical Comparison between group A and group
B regarding number of cases with atopy, accessory muscle
working, need for supplemental therapy and need for
admission.
Group A Group B v2 p Value
Atopy 2 1 0.355 1
Accessory muscle working 4 1 2.000 1
Need supplemental therapy 4 1 1.020 1
Need admission 0 1 2.000 1
34 E.A. Abdelnabi et al.plains the signiﬁcantly lower mean basal PEFR and signiﬁ-
cantly higher mean basal HR in group A shown in Tables 2
and 7 of our study.
Conclusion
Nebulized MgSo4 has a signiﬁcant bronchodilatory effect in
acute bronchial asthma. This effect is however signiﬁcantly lessthan that of nebulized salbutamol when either are used alone.
The combination of MgSo4 and salbutamol however can pro-
duce more superior bronchodilation.
Nebulized MgSo4 improves the clinical condition in pa-
tients with acute attack of bronchial asthma reﬂected by in-
crease in peak expiratory ﬂow rate (PEFR), oxygen
saturation (SO2) and decrease in heart rate (HR) and respira-
tory rate (RR).
Nebulized MgSo4 is well tolerated without adverse effects
especially regarding HR, thus can be considered in cardiac
patients.
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